Urge your members of Congress to support continued medical research funding
The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.
Blood is the official journal of the American Society of Hematology and the most cited peer-reviewed publication in the field. It is published weekly every Thursday, except for the last week in December, in addition to the ASH Annual Meeting Abstracts issue in November.
Blood Advances, the first journal to join the Blood family in 70 years, is a peer-reviewed, online only, open access journal. Under the direction of founding editor-in-chief Robert Negrin, MD, the inaugural issue made it's debut in December at the 58th ASH Annual Meeting and Exposition in San Diego.
Explore programs offered by ASH to support clinical and scientific hematology research
ASH's strategic plan highlighting the importance of placing hematology as a top funding priority in the healthcare community
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Raje and Dr. Yee cover efforts to identify new pathways to treat multiple myeloma relapse.
Dr. Hoggatt, Dr. Rhee and Dr. Mercier cover efforts to grow red blood cells, platelets, cancer-killing T-cells and many other cell and tissue types to treat patients, specifically growing enough hematopoietic stem cells.
Dr. Raetz looks at a study that shows response-based therapy in both children and adults with ETP-ALL is effective.
The National Center for Advancing Translational Sciences (NCATS) released a request for information soliciting input on the use of viral vectors as platforms for therapeutic gene delivery to specific organs or cell types, and how such platforms might be developed most efficiently in clinical trials for the treatment of multiple diseases.
On July 13, 2017, the U.S. Senate released an updated
version of the Better Care Reconciliation Act (BCRA), legislation to repeal
large provisions of the Affordable Care Act (ACA).
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology